Rat Model Global Market Report 2024

The rat model market has grown strongly in recent years. It will grow from $1.56 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The expansion observed during the historical period can be attributed to a surge in the demand for preclinical research, augmented government funding, heightened research needs, initiatives in drug development, and the escalating prevalence of chronic diseases.

The rat model market is expected to see strong growth in the next few years. It will grow to $2.34 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The anticipated growth in the forecast period can be ascribed to the increasing applications in personalized medicine, a rising demand for animal models in drug discovery, a growing emphasis on disease prevention, the expansion of the biopharmaceutical industry, innovations in imaging techniques, and sustained support from both government and private funding sources. Key trends expected in the forecast period encompass global collaborations in research, technological advancements in imaging, the integration of omics technologies, progress in genome editing techniques, a heightened significance of rat models in disease research, and the emergence of personalized medicine with a focus on customized rat models.

The anticipated growth of the rat model market is expected to be significantly boosted by the increasing incidence of chronic diseases. Chronic diseases, characterized by lasting a year or longer and requiring continuous medical care, are on the rise, thereby elevating the demand for rat models. These models play a pivotal role in studying the pathogenesis, immune responses, and treatment of chronic infections, providing crucial insights for the development of new therapies. As per a report by the National Institutes of Health (NIH), the United States is projected to witness a 99.5% increase in individuals aged 50 and older with at least one chronic illness, from 71.522 million in 2020 to 142.66 million in 2050. Additionally, the number of people with multimorbidity is expected to rise by 91.16%, reaching 14.968 million in 2050. Consequently, the growing prevalence of chronic diseases is a key driver for the rat model market.

The surge in demand for medicines is poised to propel the growth of the rat model market in the foreseeable future. Rat models serve as valuable tools for researchers conducting studies on various medicines due to their ease of handling and smaller size compared to other complex mammals such as primates. This convenience contributes to the increased demand for rat models in the market. For instance, data from the European Federation of Pharmaceutical Industries and Associations reveals that North America accounted for 49.1% of global pharmaceutical sales in 2021, surpassing Europe's share of 23.4%. Therefore, the escalating demand for medicines is a key factor driving the rat model market.

Major players in the rat model market are actively pursuing strategic partnerships for preclinical research, particularly in areas such as oncology and other therapeutic domains. By collaborating with companies specializing in rat models, these firms can focus on their core business activities while benefiting from the expertise, efficiency, and cost-effectiveness of these specialized providers, which possess established infrastructure and resources for generating rat models. One notable example is the partnership between Hera BioLabs, a US-based biotechnology company, and Charles River Laboratories, International Inc., a US-based pharmaceutical company. In March 2022, they joined forces for the commercialization of Hera's SRG rat, also known as OncoRat. Under this collaboration, Charles River will handle the breeding, distribution, sale, and marketing of the SRG rat directly to the preclinical research community. The SRG rat, characterized as a highly immunodeficient rat, is well-suited for xenograft or PDX studies, offering distinct advantages over mouse models for in vivo efficacy evaluation of potential cancer therapies. This model addresses limitations seen in smaller mouse models, allowing for larger tumor growth, simplified surgeries, and increased tissues and serum for analyses, including repeat sampling.

Prominent players in the rat model market are strategically investing to meet increasing demand and expand their customer base. Strategic investments in rat models involve targeted financial and operational initiatives to improve genetic engineering, technological advancements, collaborative partnerships, and market expansion to advance research and applications in biomedical sciences. In June 2021, Biocytogen, a US-based biotechnology company specializing in antibody drug research and development through innovative genetically engineered animal models, successfully secured a substantial funding amount in a new financing round. This strategic funding is anticipated to significantly enhance the value and functionality of the company's technology platforms. Biocytogen utilizes its foundational gene editing technology to independently develop mouse platforms for fully human antibody discovery, including RenMab and RenLite, both holding independent intellectual property rights. By implementing these platforms, Biocytogen has evolved from a contract research and development organization (CRO) to an international biotechnology company with comprehensive expertise spanning the entire spectrum of new drug research and development. A key project in Biocytogen's portfolio is the RenMice HiTS Platform, a large-scale, high-efficiency antibody discovery and screening system.

In 2021, Inotiv, Inc., a US-based contract research organization (CRO) specializing in nonclinical and analytical services, successfully completed the acquisition of Envigo RMS Holding Corp. for a total deal value of $271.0 million. This strategic agreement is aligned with the respective business goals of both companies and is expected to facilitate the streamlined advancement of novel medicines and medical devices through the critical stages of discovery and preclinical development. Envigo RMS Holding Corp., the acquired entity, is based in the United States and is known for providing research rat models and related services in the field.

Major companies operating in the rat model market report are Genoway S.A., Biomere, Transposagen Biopharmaceuticals Inc., Horizon Discovery Group PLC, Transviragen Inc., Charles River Laboratories International Inc., Taconic Biosciences Inc., Envigo Ltd., Laboratory Corporation of America Holdings, Janvier Labs, Harlan Laboratories Inc., Sage Path Labs, Applied StemCell Inc., Regenera Pharma Ltd., Cyagen Biosciences Inc., Ozgene Pty Ltd, Yecuris Corporation, Hera BioLabs Inc., Beijing Biocytogen Co. Ltd., Ingenious Targeting Laboratory, InVivos Pte Ltd., Kymab Limited, Mirimus Inc., Pharmaron Beijing Co. Ltd., PolyGene AG, Shanghai Model Organisms Center Inc., Sino Biological Inc., Synthego Corporation, Transgenic Inc., ViGene Biosciences Inc., Viva Biotech Holdings, WuXi AppTec Co. Ltd.

North America was the largest region in the rat model market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global rat model market report during the forecast period. The regions covered in the rat model market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rat model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Various types of rat models are available, including knockout, outbred, inbred, hybrid, immunodeficient, and conditioned models. In the context of knockout models, scientists modify or replace a gene to deactivate it, providing a valuable tool for studying the effects of specific gene alterations. Services provided encompass cryopreservation, breeding, re-derivation, genetic testing, and quarantine, utilizing technologies such as nuclear transferase, microinjection, and embryonic stem cells. These services cater to a range of applications, including oncology, neurology, immunology, toxicology, and more.

The rat models market research report provides rat models market statistics, including the rat models industry's global market size, regional shares, competitors with a rat models market share, detailed rat models market segments, market trends, and opportunities, and any further data you may need to thrive in the rat models industry. This rat models market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rat model market includes revenues earned by entities by providing services such as DNA preparation, genotyping services, knock-in, or transgenic rat or mouse model creation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.